ReviewSurgical pathology clinics2019
Prognostic and Predictive Biomarkers in Diffuse Large B-cell Lymphoma.
Review in Surgical pathology clinics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Gene Expression Profiling Provides an Improved Characterization ofJournal of personalized medicine · 2025Article
- MicroRNAs implicated in canine diffuse large B-cell lymphoma prognosis.FEBS open bio · 2024Article
- Tumor Biology Hides Novel Therapeutic Approaches to Diffuse Large B-Cell Lymphoma: A Narrative Review.International journal of molecular sciences · 2024Review
- Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma.Nature medicine · 2024Article
- Focal adhesion kinase as a new player in the biology of onco-hematological diseases: the starting evidence.Frontiers in oncology · 2024Review
- Progress in deciphering the role of p53 in diffuse large B-cell lymphoma: mechanisms and therapeutic targets.American journal of cancer research · 2024Review
- Article
- FOXP1-GINS1 axis promotes DLBCL proliferation and directs doxorubicin resistance.Journal of Cancer · 2023Article
- Role of Polyamines as Biomarkers in Lymphoma Patients: A Pilot Study.Diagnostics (Basel, Switzerland) · 2022Article
- HOXD3 Up-regulating KDM5C Promotes Malignant Progression of Diffuse Large B-Cell Lymphoma by Decreasing p53 ExpressionBalkan medical journal · 2022Article
- Identification and Validation of a DNA Damage Repair-Related Signature for Diffuse Large B-Cell Lymphoma.BioMed research international · 2022Article
- Transformed Lymphoma Is Associated with a Favorable Response to CAR-T-Cell Treatment in DLBCL Patients.Cancers · 2021Article
- Elevated M-MDSCs in Circulation Are Indicative of Poor Prognosis in Diffuse Large B-Cell Lymphoma Patients.Journal of clinical medicine · 2021Article
- A Clinical Triad with Fatal Implications: Recrudescent Diffuse Large B-cell Non-Hodgkin Lymphoma Presenting in the Leukemic Phase with an Elevated Serum Lactic Acid Level and Dysregulation of the TP53 Tumor Suppressor Gene - A Case Report and Literature Review.Clinical medicine insights. Blood disorders · 2021Article
- Case Report: Identification of Potential Prognosis-RelatedFrontiers in endocrinology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.